New triple therapy could extend life for esophageal cancer patients
NCT ID NCT06964568
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding immunotherapy (a drug that helps the immune system fight cancer) after standard chemotherapy and radiation can help people with advanced esophageal cancer live longer without the disease getting worse. About 452 adults with a specific type of esophageal cancer will be randomly assigned to receive either immunotherapy or just monitoring after their initial treatment. The goal is to see if the immunotherapy maintenance improves outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a simple supplement soothe Radiation-Damaged rectums?
- Can imaging reveal how radiation shapes marrow recovery?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- AI biomarker may reveal who responds to esophageal cancer immunotherapy